Duritect™ tests
Patients and Caregivers Duritect™ for patients and caregivers
Get tested for Alzheimer’s disease
Get tested for Parkinson’s disease
Provider Duritect™ for healthcare providers
Duritect-AD™ test for Alzheimer’s disease
Duritect-PD™ test for Parkinson’s disease
Science and Research
News and events
About us

Duritect-PD™ test for Parkinson’s disease

A rapid and reliable disease risk assessment test for patients with suspected Parkinson’s disease, to help you arrive at a diagnosis earlier.1

Try Duritect-PD™ for Parkinson's Disease
Image(2)
Image(2)

Assess the risk of Parkinson’s
with Duritect-PD™

When a patient has signs or symptoms of physical impairment that suggest they might have Parkinson’s disease (PD), a Duritect™ blood test could help streamline the diagnostic process.1

Duritect-PD™ provides a reliable risk score for PD, allowing you to quickly rule out other conditions with similar symptoms.1 This reduces uncertainty, improves the efficiency of diagnostic resources, and ensures patients receive timely and appropriate care.2,3

Earlier diagnosis could enable earlier intervention and treatment, which may improve your patients’ outcomes and quality of life.2,3

Learn more on this page
  • Features and benefits
  • Key facts about Duritect-PD™
  • Try Duritect™ in your clinical practice

About the test

Duritect-PD™ is a disease "risk assessment" test. It combines a simple blood test with machine learning analysis to assess the patient’s risk of having PD.1

Duritect-PD™ is for prescription use only.

The test looks for the presence of specific autoantibodies in the patient’s blood as biomarkers of the disease.1 It combines the measurement of autoantibody signatures detected in serum isolated from peripheral whole blood into a numeric Parkinson’s Disease Risk Score (PDRS).

The risk score indicates a higher or lower likelihood that the patient’s symptoms are due to PD.1 Test results should be interpreted by healthcare professionals in conjunction with other clinical assessments and diagnostic tools, consistent with professional standards of clinical practice.1

Features and benefits

Duritect-AD™ helps you to categorize patients by risk level and make swift, informed decisions.
detact early
Highly accurate4
The highly accurate risk score indicates the probability of PD-related pathology being present.
Clear and easy to understand
Clear and easy to understand
Each patient gets a report that shows either an increased or typical risk that can easily be interpreted.1
simple admin
Simple to administer
The test is easy to carry out. It involves a blood draw and no specific timing or preparation is needed.
min invasive
Minimally invasive
Collecting a blood sample is a quick and least invasive way to assess your patient’s risk of having PD.
Rapid
Rapid
The test results are generally available 48 to 72 hours after the laboratory receives your blood sample.*
affordable
Affordable
The test is a cost-effective way to assess the risk of PD as part of your initial evaluations.

Key facts about Duritect-PD™

This information is intended for medical professionals and covers the clinical use of the test.

Indications for use

Duritect-PD™ is intended for use as an aid in diagnostic evaluation of adult patients:1

  • Age 50+
  • Presenting with signs/symptoms of cognitive impairment that could indicate PD or other causes of cognitive decline

The test is not intended for:1

  • Screening asymptomatic patients
  • Stand-alone diagnostic purposes
  • Definitively confirming/excluding a diagnosis of PD or other cognitive conditions

The performance of the risk score has not been established for:1

  • Predicting development of dementia due to PD or other neurologic conditions
  • Monitoring responses to therapies
The testing process

The Duritect-PD™ test process is simple:

  • Order: Order the test using the requisition form found online or in the sample collection kit.
  • Payment: The patient can pay for the test online.
  • Sample collection: Carry out a blood draw according to the instructions for use.
  • Packaging and shipping: Use the labeled envelope to send the sample to our laboratory for processing.
  • Analysis: The sample is analyzed using a combination of scientific approaches.
  • Results: A report is generally available to view 48–72 hours after the laboratory receives the patient’s blood sample.*
What the test looks for

Duritect-PD™ measures levels of specific autoantibodies in the blood to assess a patient’s risk of having ongoing PD pathology.1

Autoantibodies are immune proteins that respond to the production of disease-specific debris generated as a result of ongoing disease pathology. When ongoing disease pathology results in cellular death and debris, the immune system increases production of disease-specific autoantibodies to bind and clear this antigenic debris.

Research has identified several antigen targets associated with Parkinson’s disease pathology:5-13

Antigen target α-synuclein pathology Lewy body formation Mitochondrial dysfunction Neuro-inflammation Blood-brain
barrier integrity
Marker 1 Group 291 Group 291 x x x
Marker 2 x x Group 291 x x
Marker 3 x x x Group 291 Group 291
Marker 4 x x x Group 291 Group 291

 

Duritect-PD™ looks for the autoantibodies that bind to these antigens as biomarkers of the disease.

You can read more about using autoantibodies as biomarkers on the Science and Research page.

The test results

The Duritect-PD™ test determines the Parkinson’s Disease Risk Score (PDRS):1

  • Patients with a higher score (60 or greater) are considered to be at an increased risk of PD pathology. They should be referred for additional diagnostic, cognitive, and physiological examinations consistent with professional guidelines for PD diagnosis.1
  • Patients with a lower score (40 or lower) are considered to be at a typical risk of PD pathology. They should be monitored and evaluated for other conditions that mimic early symptoms of PD, consistent with professional clinical guidelines.1
  • Patients with an intermediate score (between 40 or 60) are considered to be inconclusive of AD pathology. The test should be repeated and if same result is obtained, the patient should be retested within 6-12 months.1

Test results should be interpreted in conjunction with other clinical assessments and diagnostic tools, consistent with professional standards of clinical practice.1

Try Duritect-PD™ 
in your clinical practice

Are you passionate about advancing the diagnosis and treatment of Parkinson’s disease? Do you thrive on innovation and the opportunity to shape the future of healthcare?

If you’re involved in diagnosing and treating neurodegenerative diseases, we invite you to join our Early Adopters Program and try Duritect™ now.

Find out more
Duritect™ embodies our dedication to innovation in healthcare – delivering a fast and highly accurate test, to help you detect the presence of a particular disease and begin treating your patients much earlier
Prof. Robert Nagele, PhD
CSO Durin Life Sciences

Abbreviations and references

  1. [Duritect-AD™. Indications for use. Durin Life Sciences. 2024.]
  2. Pagán FL. Improving outcomes through early diagnosis of Parkinson’s disease. Am J Manag Care. 2012;18:S176-S182.
  3. Rees RN, Acharya P, Schrag A, Noyce AJ. An early diagnosis is not the same as a timely diagnosis of Parkinson’s disease. F1000 Res. 2018;7(F1000 Faculty Rev):1106.
  4. Duritect™’s analytical and clinical validation data, company internal. 2025.
  5. Ebneth A, Drewes G, Mandelkow EM, Mandelkow E. Phosphorylation of MAP2c and MAP4 by MARK kinases leads to the destabilization of microtubules in cells. Cell Motil Cytoskeleton. 1999;44(3):209–224.
  6. Alt C, Laschinger M, Engelhardt B. Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis. Eur J Immunol. 2002;32(8):2133–2144.
  7. Mandelkow EM, Thies E, Trinczek B, Biernat J, Mandelkow E. MARK/PAR1 kinase is a regulator of microtubule-dependent transport in axons. J Cell Biol. 2004;167(1):99–110.
  8. Wu Q, DiBona VL, Bernard LP, Zhang H. The polarity protein partitioning-defective 1 (PAR-1) regulates dendritic spine morphogenesis through phosphorylating postsynaptic density protein 95 (PSD-95). J Biol Chem. 2012;287(36):30781–30788.
  9. Su M-L, Chang T-M, Chiang C-H, et al. Inhibition of chemokine (C-C motif) receptor 7 sialylation suppresses CCL19-stimulated proliferation, invasion and anti-anoikis. PLoS One. 2014;9(6):e98823.
  10. Williams JL, Holman DW, Klein RS. Chemokines in the balance: maintenance of homeostasis and protection at CNS barriers. Front Cell Neurosci. 2014:8:154.
  11. Henderson MX, Chung CHY, Riddle DM, et al. Unbiased proteomics of early Lewy body formation model implicates active microtubule affinity-regulating kinases (MARKs) in synucleinopathies. J Neurosci. 2017;37(24):5870–5884.
  12. Yang Y, Kimora-Ohba S, Thompson JF, et al. Vascular tight junction disruption and angiogenesis in spontaneously hypertensive rat with neuroinflammatory white matter injury. Neurobiol Dis. 2018;114:95–110.
  13. Sogorb-Esteve A, Swift IJ, Woollacott IOC, Warren JD, Zetterberg H, Rohrer JD. Differential chemokine alteration in the variants of primary progressive aphasia-a role for neuroinflammation. J Neuroinflam. 2021;18(1):224.

Contact Us

© Durin Life Sciences, 2 Medical Center Dr, 213A, Stratford, NJ 08084.
All rights reserved.